Povezanost polimorfizma TM6SF2 rs58542926 T/C gena sa hepatocelularnim karcinomom: meta-analiza.
BMC cancer
Sažetak istraživanja
Pozadina Hepatocelularni karcinom (HCC) je šesti najčešći malignitet u svijetu. Više prethodnih studija je procijenilo vezu između polimorfizma gena TM6SF2 i rizika od razvoja HCC-a, sa različitim zaključcima. Da bismo procijenili povezanost polimorfizma T/C gena TM6SF2 rs58542926 sa karcinomom jetre, izvršili smo trenutnu meta-analizu.
Methods This study queried the MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to April 2019. Case-control studies assessing the relationship between TM6SF2 rs5854292 locus polymorphism and liver cancer were selected according to inclusion and exclusion criteria. Za analizu podataka korišten je softver Stata 12.0.
Rezultati Ukupno 5 članaka, koji obuhvataju 6873 pacijenta, ispunili su kriterijume za uključivanje i uključeni su u metaanalizu. Statistical analysis showed that the TM6SF2 gene polymorphism was significantly associated with liver cancer in the allele contrast, dominant, recessive and over dominant models (T vs C, OR = 1.621, 95%CI 1.379-1.905; CT + TT vs CC. OR = 1.541, 95%CI 1.351-1.758; TT vs CT + CC, OR = 2,897, 95%CI 1,690-4,966 CC + TT vs TC, OR = 0,693, 95%CI 0,576-0,834); Eggerov test nije otkrio značajnu pristrasnost publikacije.
Zaključak Ovi nalazi ukazuju na značajnu povezanost polimorfizma TM6SF2 gena sa rizikom od HCC u cijeloj proučavanoj populaciji.
Prikaži originalni naslov i sažetak na engleskom
Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.
Background Hepatocellular carcinoma (HCC) is the sixth-most common malignancy worldwide. Multiple previous studies have assessed the relationship between TM6SF2 gene polymorphism and the risk of developing HCC, with discrepant conclusions reached. To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis.
Methods This study queried the MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to April 2019. Case-control studies assessing the relationship between TM6SF2 rs5854292 locus polymorphism and liver cancer were selected according to inclusion and exclusion criteria. The Stata 12.0 software was employed for data analysis.
Results A total of 5 articles, encompassing 6873 patients, met inclusion criteria and were included in the meta-analysis. Statistical analysis showed that the TM6SF2 gene polymorphism was significantly associated with liver cancer in the allele contrast, dominant, recessive and over dominant models (T vs C, OR = 1.621, 95%CI 1.379-1.905; CT + TT vs CC. OR = 1.541, 95%CI 1.351-1.758; TT vs CT + CC, OR = 2.897, 95%CI 1.690-4.966; CC + TT vs TC, OR = 0.693, 95%CI 0.576-0.834). The Egger's test revealed no significant publication bias.
Conclusion The present findings suggest a significant association of TM6SF2 gene polymorphism with HCC risk in the entire population studied.
Izvorni podaci
- DOI
- 10.1186/s12885-019-6173-4
- PMID
- 31752753
- PMCID
- PMC6868855
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom